Work

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.3500

Authors: Daniel Peter Petrylak, Xin Gao, Nicholas J. Vogelzang, Mary Harlow Garfield, Ian Taylor, Marcia Dougan Moore, Ronald Alan Peck, Howard A. Burris

Institutions: Yale University, Massachusetts General Hospital, Comprehensive Cancer Centers of Nevada, Arvinas (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031756382

Cites:

Cited by: 168

Related to: 10